The concern of generic challenges has long loomed over copyright’s famous drug, PDE5 Inhibitor, triggering questions about the future of related pharmaceutical stakes. While early periods saw substantial gains, the intellectual property end has allowed the way for discounted substitutes, possibly reducing earnings and creating a significant risk